NCT06384196 Identity-Based Transdiagnostic Therapy for Young People With Anxiety and Depression
| NCT ID | NCT06384196 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Barcelona |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 138 participants |
| Start Date | 2025-05-02 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 138 participants in total. It began in 2025-05-02 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Depression and anxiety are the most prevalent mental disorders among both the general population and young adults, and transdiagnostic treatments for these patients are mostly based on cognitive-behavioral therapy (CBT). Based on common (transdiagnostic) principles of treatment (e.g., emotional exposure), these approaches have proliferated and demonstrated their efficacy in comparison to disorder-specific treatments. Although there are a few transdiagnostic approaches for children and adolescents, it was not possible to not find anyone targeting young people. For this reason, the investigators proposed the Identity-Based Transdiagnostic Therapy (IBTT) as a new treatment modality ideally created to address the challenge of improving the outcomes of psychotherapy for young adults with anxiety and/or depression. The IBTT is a psychological treatment for emotional disorders specifically designed for the youths in terms of their attitudes to treatment (attractiveness, engagement), and highly personalized to their construal of self and others. This project will allow testing the hypothesis that a novel brief psychotherapeutic intervention, IBTT, will be more efficacious in the treatment of the anxiety and/or depression of young adults than the well-established CBT-based Unified Protocol.
Eligibility Criteria
Inclusion Criteria: • Participants with symptoms of depression and/or anxiety as their primary complaint. Exclusion Criteria: * Participants with post-traumatic stress, bipolar and substance use disorders, psychotic symptoms, organic brain dysfunction, marked suicidal ideation and/or intellectual disability. * Participants receiving psychological treatment, unless it is suspended at the time of inclusion in the study itself in agreement with their therapist. * Participants for whom the use of virtual reality may pose a risk, even a minor risk (epilepsia, acute otorhinolaryngological processes or recent interventions, severe cardiovascular disease, unstable hypertension, and pregnancy). * Participants with substantial visual, hearing, and cognitive deficits. * Participants who do not have enough competence to communicate in Spanish or Catalan.
Contact & Investigator
Guillem Feixas, PhD
PRINCIPAL INVESTIGATOR
University of Barcelona
Frequently Asked Questions
Who can join the NCT06384196 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 29 Years, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06384196 currently recruiting?
Yes, NCT06384196 is actively recruiting participants. Contact the research team at gfeixas@ub.edu for enrollment information.
Where is the NCT06384196 trial being conducted?
This trial is being conducted at Badalona, Spain, Barcelona, Spain.
Who is sponsoring the NCT06384196 clinical trial?
NCT06384196 is sponsored by University of Barcelona. The principal investigator is Guillem Feixas, PhD at University of Barcelona. The trial plans to enroll 138 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.